WaterMill Asset Management refutes Ziopharm Oncology's 'desperate' campaign

WaterMill Asset Management, which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, responded to "the low-road campaign that the incumbent Board of Directors has apparently initiated in order to smear Holger Weis and misrepresent his more than six-year tenure at DemeRx," the former said. WaterMill believes this "seemingly underhanded stunt" only reinforces the need for meaningful and urgent boardroom change. WaterMill added that, "It is important to highlight that the incumbent Board's desperate attack on Weis comes on the heels of Institutional Shareholder Services, a leading independent proxy voting advisory firm, recommending that Ziopharm shareholders vote for boardroom change on WaterMill's WHITE consent card. ISS supports the addition of two WaterMill nominees and the removal of two incumbents."